Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to 21.29%.

  • Harmony Biosciences Holdings' EBITDA Margin fell 38800.0% to 21.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.46%, marking a year-over-year increase of 43300.0%. This contributed to the annual value of 20.37% for FY2024, which is 18000.0% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its EBITDA Margin stood at 21.29% for Q3 2025, which was down 38800.0% from 19.84% recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' EBITDA Margin peaked at 74.91% during Q3 2022, and registered a low of 11.92% during Q3 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 24.37% (2024), whereas its average is 23.86%.
  • In the last 5 years, Harmony Biosciences Holdings' EBITDA Margin soared by 868200bps in 2022 and then tumbled by -509000bps in 2023.
  • Harmony Biosciences Holdings' EBITDA Margin (Quarter) stood at 24.9% in 2021, then soared by 52bps to 37.83% in 2022, then tumbled by -57bps to 16.11% in 2023, then soared by 51bps to 24.37% in 2024, then dropped by -13bps to 21.29% in 2025.
  • Its EBITDA Margin was 21.29% in Q3 2025, compared to 19.84% in Q2 2025 and 24.76% in Q1 2025.